Prognostic factors for overall survival in patients with primary duodenal adenocarcinoma. 2021

Teng-Yan Li, and Qi-Chen Chen, and Hong Zhao, and Ye-Fan Zhang, and Jian-Jun Zhao, and Jian-Qiang Cai
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

BACKGROUND The complete resection of primary duodenal adenocarcinoma (PDA) offers a chance for a cure, but the clinical and pathological characteristics of survivors have not been well studied. METHODS Patients with stage I-III PDA who underwent surgical resection between 2013 and 2018 were identified retrospectively and followed until December 2019. All patients are from the Cancer Hospital Chinese Academy of Medical Sciences. The clinical and pathological information of the patients, such as age, gender, tumor location, operative procedure, pathologic features, TNM stage, common presenting symptoms, lymph node dissection status, serum tumor markers, etc., was collected in detail. The KaplanMeier method and a Cox proportional hazards model were used for the survival analysis. RESULTS In total, 85 patients with PDA were eligible for this study. Among these patients, 48 were male (56.5%), 37 were female (43.5%), the median age was 59 (range, 22-79) years, 44 (51.8%) patients were aged <60 years, and 41 (48.2%) patients were aged ≥60 years. The 1-, 3-, and 5-year survival rates were 93.7%, 79.4%, and 64.9%, respectively. The median overall survival (OS) was 27 months (range, 2-82 months), and the median follow-up was 27 months (range, 3-82 months). The patients with stage III disease had the worst prognosis (P=0.001). The univariate analysis showed that lymph node positivity (P=0.000), the N stage (P=0.000), the TNM stage (P=0.001) and carbohydrate antigen 19-9 (CA19-9) positivity (P=0.038) were related to OS. However, the total number of lymph nodes (LN) retrieved (P=0.723), tumor differentiation (P=0.136), carcinoembryonic antigen (CEA) (P=0.812), gender (P=0.477), operation type (P=0.860), tumor size (P=0.869), tumor site (P=0.120), age (P=0.733), intraoperative blood loss (P=0.660), and intraoperative blood transfusion (P=0.748) were not correlated with OS. The multivariate analysis suggested that the lymph node status was an independent prognostic risk factor for OS. CONCLUSIONS In our study the median OS was 27 months (range, 2-82 months), and the 5-year survival rates was 64.9%. The lymph node status was the only prognostic factor for OS in PDA.

UI MeSH Term Description Entries
D008197 Lymph Node Excision Surgical excision of one or more lymph nodes. Its most common use is in cancer surgery. (From Dorland, 28th ed, p966) Lymph Node Dissection,Lymphadenectomy,Dissection, Lymph Node,Dissections, Lymph Node,Excision, Lymph Node,Excisions, Lymph Node,Lymph Node Dissections,Lymph Node Excisions,Lymphadenectomies,Node Dissection, Lymph,Node Dissections, Lymph
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

Teng-Yan Li, and Qi-Chen Chen, and Hong Zhao, and Ye-Fan Zhang, and Jian-Jun Zhao, and Jian-Qiang Cai
March 2011, The Korean journal of internal medicine,
Teng-Yan Li, and Qi-Chen Chen, and Hong Zhao, and Ye-Fan Zhang, and Jian-Jun Zhao, and Jian-Qiang Cai
October 2008, World journal of surgery,
Teng-Yan Li, and Qi-Chen Chen, and Hong Zhao, and Ye-Fan Zhang, and Jian-Jun Zhao, and Jian-Qiang Cai
February 2021, Cancer reports (Hoboken, N.J.),
Teng-Yan Li, and Qi-Chen Chen, and Hong Zhao, and Ye-Fan Zhang, and Jian-Jun Zhao, and Jian-Qiang Cai
January 2011, International surgery,
Teng-Yan Li, and Qi-Chen Chen, and Hong Zhao, and Ye-Fan Zhang, and Jian-Jun Zhao, and Jian-Qiang Cai
April 1991, Annals of oncology : official journal of the European Society for Medical Oncology,
Teng-Yan Li, and Qi-Chen Chen, and Hong Zhao, and Ye-Fan Zhang, and Jian-Jun Zhao, and Jian-Qiang Cai
January 2016, Cirugia y cirujanos,
Teng-Yan Li, and Qi-Chen Chen, and Hong Zhao, and Ye-Fan Zhang, and Jian-Jun Zhao, and Jian-Qiang Cai
December 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Teng-Yan Li, and Qi-Chen Chen, and Hong Zhao, and Ye-Fan Zhang, and Jian-Jun Zhao, and Jian-Qiang Cai
August 2014, World journal of gastroenterology,
Teng-Yan Li, and Qi-Chen Chen, and Hong Zhao, and Ye-Fan Zhang, and Jian-Jun Zhao, and Jian-Qiang Cai
January 2014, Acta medica academica,
Teng-Yan Li, and Qi-Chen Chen, and Hong Zhao, and Ye-Fan Zhang, and Jian-Jun Zhao, and Jian-Qiang Cai
January 2021, Frontiers in oncology,
Copied contents to your clipboard!